Topical Bevacizumab for Preventing Recurrent Pterygium

NCT01311960 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

24

Enrollment

OTHER

Sponsor class

Conditions

Pterygium
Bevacizumab
VEGF
Anti-VEGF

Interventions

DRUG: bevacizumab eye drop 0.05%
DRUG: normal saline 0.9%

Sponsor

Chulalongkorn University